Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Asso...
Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A.sub.2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial
About this item
Full title
Author / Creator
Publisher
Public Library of Science
Journal title
Language
English
Formats
Publication information
Publisher
Public Library of Science
Subjects
More information
Scope and Contents
Contents
Background and Objectives Darapladib is a lipoprotein-associated phospholipase A.sub.2 (Lp-PLA.sub.2) inhibitor. This study evaluated the pharmacokinetics, pharmacodynamics and safety of darapladib in healthy Chinese subjects. Methods Twenty-four subjects received darapladib 160 mg orally, approximately 1 hour after a standard breakfast, as a singl...
Alternative Titles
Full title
Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A.sub.2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracacademiconefile_A431582978
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracacademiconefile_A431582978
Other Identifiers
ISSN
1932-6203
E-ISSN
1932-6203
DOI
10.1371/journal.pone.0139862
